Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Transgene Secures Two Year Runway As Oncolytic Vaccine Enters Phase III

This article was originally published in Scrip

Executive Summary

Transgene SA's share price has received a welcome boost this week on two separate pieces of news. Transgene's development partner SillaJen Inc. has begun the first Phase III trial of the oncolytic immunotherapy Pexa-Vec in patients with advanced liver cancer. Also, the company unveiled a new strategic development plan as well as the securing of €30m new financing.


Related Content

Transgene’s Moment Of Truth Approaches
NICE Clears Amgen’s Imlygic At Second Attempt, Combo Results Keenly Awaited